Otherindependent cross-checkfull text checked★ key study I-CAN-128 standard review
Critique: registry 'CAM' is really alternative treatment instead of standard care
When "CAM" is not CAM: Interpreting national cancer database analyses in breast cancer.
Overview
Jeitler M et al.. Oncologist 2026 · PMID 42135607 · DOI 10.1093/oncolo/oyag187
Experts note that the US registry studies capture people who used non-medical alternatives as cancer treatment, not complementary therapies in general.
Does the study support the specific claim? Unclear · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Critique NCDB CAM studies.
- How was the study done?
Commentary.
- How many people, animals or samples were studied?
Not applicable.
- What was actually found?
Exposure narrow; some methods unclear.
- How large was the observed effect?
Not applicable.
- What do the results mean in everyday life?
The warning applies to replacing treatment, not to supportive therapies.
- What are the study's limitations?
No new data.
- What does it say about Elawady's specific claim?
Sharpens, does not weaken, the safety message.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Precise size of harm.
Scientific in-depth review
1. Full reference
- Authors
- Jeitler M et al.
- Journal
- Oncologist
- Year
- 2026
- Identifier
- PMID 42135607 DOI 10.1093/oncolo/oyag187
- Verification
- verified – PubMed efetch 2026-10-26 + Crossref
- Retracted
- no
- Corrections
- none
- Extent checked
- full text
- Conflicts of interest and funding
None declared; Tübingen open-access fund; ChatGPT used for language support (declared)
2. Research question
Do NCDB 'CAM' variables capture complementary and alternative medicine as understood clinically?
3. Study design and population
- Study design
- Other – Commentary on NCDB analyses of CAM (critique of I-CAN-101 and of Johnson et al.)
- Population
not applicable
- Country
Germany (authors)
- Period
Published 2026
- Sample size
not applicable
- Inclusion and exclusion criteria
not applicable
4. Methods and endpoints
- Exposure / intervention
NCDB coding of treatment by non-medical personnel
- Comparator
not applicable
- Endpoints
not applicable
- Statistical methods
not applicable
5. Actual results
- Results
Full text read: the NCDB exposure is a narrow registry-coded subgroup (273 CAM-only among 2.15 million) and not CAM or integrative oncology in general (35.3% of US adults with recent cancer use complementary approaches; 2.3% for cancer treatment). The adjusted Cox model does not clearly handle immortal time; receptor status, HER2, grade were not adjusted; stage missing in 34-44%. The authors state that 'concerns about replacement of standard oncologic care' are not misplaced, and recommend calling the exposure 'registry-coded nonmedical alternative cancer treatment'.
- Absolute risks
not applicable
- Authors' conclusion
Database studies may identify alternative-treatment behaviour but do not represent CAM or integrative oncology as a whole; precise terminology needed.
6. Strengths
- Specific methodological critique
7. Weaknesses
- Commentary; no new data
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- not assessable
- Rationale
Commentary.
9. Assessment of the statistical interpretation
Not applicable.
10. Relevance to the specific claim
Limits the interpretation of I-CAN-101 (especially the combination group and 'CAM' wording) but confirms that the replacement of standard treatment - the behaviour Elawady recommends - is a valid concern.
11. Independent contrary findings
Argues against generalising NCDB findings to supportive complementary care.
12. Transferability to Germany and Europe
High.
13. Overall methodological judgement
Important nuance: the evidence speaks against replacing treatment, not against supportive complementary care.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | not assessable |
| Precision of results | not applicable |
| Directness | direct |
| Reproducibility | unknown |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
15. Linked fact checks
- Cancer will respond to the Tayebat system; a patient with a malignant tumour should start the system now (diet as cancer treatment). – Studies with mixed or unclear results